Fabry Disease

Type: Keyphrase
Name: Fabry Disease
First reported Sep 07 2014 - Updated Sep 07 2014 - 1 reports

Israeli Company Reports It is Ready to Mass-Produce Ebola Cure for All of Africa

Professor Yoseph Shaaltiel, Protalix Executive VP Research and Development stated that his company can immediately begin producing the experimental anti-Ebola ZMapp drug, the only drug that has proven to be an effective Ebola cure. Dr. Kent Brantly, the ... [Published Cutting Edge News - Sep 07 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Genzyme Corporation To Move 500-Employees To New Space In Westborough

September 5, 2014By Krystle Vermes , BioSpace.com Breaking News StaffCambridge-based Genzyme Corporation ( GENZ ) has announced that it will be moving 500 employees from operations in Framingham, Mass., to Westborough, Mass. They will be relocated to ... [Published BioSpace - Sep 05 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 2 reports

Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs

CARMIEL, Israel, Aug. 28, 2014 (GLOBE NEWSWIRE) -- . (NYSE MKT:PLX) (TASE:PLX), announced today that it will host a conference call on Wednesday, September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly ... [Published EMoneyDaily - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

Amicus Therapeutics (FOLD) Stock Rises on High Volume

08/28/14 - 12:40 PM EDTNEW YORK ( TheStreet ) --  Amicus Therapeutics  ( FOLD ) nearly touched a 52-week high of $7.40 on Thursday as the stock continued to rise on high volume.Last week, the company announced its potential Fabry disease treatment drug ... [Published TheStreet.com - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Amicus announces positive data from Phase III Fabry disease study

Amicus Therapeutics, Inc., a biopharmaceutical company, has announced positive 18-month data from its second Phase III study, or Study 012, with an oral small molecule chaperone, migalastat HCl, in Fabry patients with amenable mutations. Study 012 compared ... [Published Individual.com - Aug 28 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Amicus Therapeutics' Fabry Treatment Shows Positive Results In Phase 3 Trials

By C. Rajan , contributing writerAmicus Therapeutics has just announced the positive results from its second Phase 3 clinical trial of its new drug, Migalastat, to treat Fabry disease. Migalastat, Amicus' first main drug, is now closer to becoming the ... [Published Bioresearch Online - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 3 reports

Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day

– highlights Epizyme (EPZM-) as the and Panera (PNRA-) as the . In addition, provides analysis on Amicus Therapeutics (FOLD-), Sanofi (SNY-) and Shire (SHPG-). Here is a synopsis of all five stocks:: The biotech bull market is far from over due to several ... [Published Yahoo! Finance - Aug 22 2014]
First reported Aug 20 2014 - Updated Aug 21 2014 - 17 reports

Amicus seeks to upset Fabry market

Share this article: Shire's decision to ignore the US Fabry disease market triggered a ripple of anger among some patient advocates because it gave Sanofi a lock on the market, but Phase-III results from an experimental treatment by Cranbury, New Jersey's ... [Published Medical Marketing And Media - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 2 reports

Positive study results from Amicus Therapeutics

Amicus Therapeutics Inc. (Nasdaq: FOLD) reported positive results from a Phase 3 study of its Fabry disease treatment migalastat. Shares of the biopharmaceutical soared 93 cents to close at $5.5 ... [Published Chicago Daily Herald - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 3 reports

UPDATE: Apple sets intraday record; PetSmart considers sale

Tickers to Watch Apple Inc. (AAPL): Shares of the consumer-electronics giant hit an all-time high post stock split price of $100.75 Wednesday. The stock hit $100.56 on Tuesday, surpassing the old record close of $100.30 set Sept. 19, 2012, adjusted ... [Published Morningstar.com - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 6 reports

Amicus lead drug nears approval as late-stage trial succeeds

6:37 a.m. EDTBy Natalie Grover(Reuters) - Amicus Therapeutics Inc is a step closer to bringing its first drug to the market after trial data paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an ... [Published WKZO-AM - Aug 20 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

A family’s fight vs rare disease

Ever since he was a young boy, Alexander Baldoza would experience numbness and tingling, crawling sensations—like ants—crawling on both hands and feet. It got much worse when he had a cold or fever.It was only in 2010 and at 42 years old that Alexander ... [Published Philippine Daily Inquirer - Aug 15 2014]

Quotes

...of isolation for patients and families," said Jamie Ring , Genzyme's vice president of global patient advocacy and humanitarian programs, adding, "Through Expression of Hope, anyone whose life has been touched by an LSD - including caregivers, family members, and friends - is invited to use the power of art to share their unique story with the world. Our goal is to use works of art to help more people learn about the impact of LSDs and join the effort to support people affected by them."
"Our lease [in Framingham] expires at the end of the year, and as part of our standard lease renewal process, our Sanofi real estate colleagues conducted a review to confirm that remaining at the current location [is not] the best option in terms of not only cost but also amenities [and quality of office space]" Genzyme spokesman David Murdoch wrote in an statement, according to the Worcester Business Journal
John F Crowley, Chairman and CEO of Amicus TherapeuticsAmicus Therapeutics Inc., stated, "We believe that this multi-year study unequivocally demonstrates that a Fabry patient on ERT with an amenable mutation can switch safely and effectively from ERT to migalastat to treat their Fabry disease. Today is a great day for the Fabry community and for Amicus. This study was resoundingly positive and met our pre-defined criteria for success in terms of the co-primary endpoints of kidney function. These results clearly show that migalastat is comparable to ERT in slowing the progression of Fabry disease and continues to demonstrate a favorable safety profile."
"I think the interest will come," Icon Genetics COO Victor Klimyuk told Reuters. "It's typical that the big pharmapharma industry is very conservative in what they establish and what they invest in."

More Content

All (80) | News (74) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Genzyme Announces Launch of "Expression of Hope... [Published 4 Traders - Sep 18 2014]
Israeli Company Reports It is Ready to Mass-Pro... [Published Cutting Edge News - Sep 07 2014]
Genzyme Corporation To Move 500-Employees To Ne... [Published BioSpace - Sep 05 2014]
Protalix BioTherapeutics to Present at the Rodm... [Published Street Sweeper - Sep 04 2014]
Protalix Announces Conference Call to Discuss E... [Published EMoneyDaily - Aug 28 2014]
3 Reasons Sanofi's Stock Could Rise [Published Motley Fool - Aug 28 2014]
AbbVie: Growth Story Or Patent Expiration Night... [Published Seeking Alpha - Aug 28 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published Scottrade - Aug 28 2014]
Amicus Therapeutics (FOLD) Stock Rises on High ... [Published TheStreet.com - Aug 28 2014]
Amicus Therapeutics (FOLD) Stock Rises on High ... [Published The Street Latest - Aug 28 2014]
The Zacks Analyst Blog Highlights: RadioShack, ... [Published Yahoo! Finance - Aug 28 2014]
Amicus announces positive data from Phase III F... [Published Individual.com - Aug 28 2014]
East Coast Biotech Roundup: NJ Blues, Genzyme, ... [Published Xconomy - Aug 25 2014]
3 Pharma Companies That Could Deliver Breakthro... [Published Benzinga.com - Aug 25 2014]
Karnataka govt yet to disburse Rs.10 cr for ded... [Published PharmaBiz - Aug 23 2014]
Amicus Therapeutics' Fabry Treatment Shows Posi... [Published Bioresearch Online - Aug 22 2014]
Group still hopeful for passage of rare disease... [Published Philippine Daily Inquirer - Aug 22 2014]
Epizyme, Panera, Amicus Therapeutics, Sanofi an... [Published Yahoo! Finance - Aug 22 2014]
Amicus Therapeutics (FOLD) Soars on Fabry Drug ... [Published Yahoo! Finance - Aug 21 2014]
Law: Only frozen hearts could hate ice bucket vids [Published Thorold Edition - Aug 21 2014]
Positive Ph III data for Amicus’ migalastat as ... [Published Pharma Letter - Aug 21 2014]
Research and Markets: Global Lysosomal Storage ... [Published Yahoo! Finance - Aug 21 2014]
Amicus seeks to upset Fabry market [Published Medical Marketing And Media - Aug 21 2014]
Closing Update: Stocks Scratch Out Small Gains... [Published Nasdaq - Aug 20 2014]
Positive study results from Amicus Therapeutics [Published Chicago Daily Herald - Aug 20 2014]
Amicus Therapeutics’ Successful Drug Trial Resu... [Published Yahoo! Finance - Aug 20 2014]
Sector Update: Health Care Stocks Rebound Late;... [Published Nasdaq - Aug 20 2014]
Amicus Therapeutics' (FOLD) CEO John Crowley on... [Published Seeking Alpha - Aug 20 2014]
VERTEX PHARMACEUTICALS : Patent Issued for Isot... [Published 4 Traders - Aug 20 2014]
Healthcare Review: Celgene, Emisphere, NovaBay ... [Published BioMedReports - Aug 20 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Futures Little Changed With Fed Minutes On Tap [Published Clusterstock - Aug 20 2014]
By Chuck Mikolajczak NEW YORK (Reuters) - Stock futures were little changed on Wednesday after the S&P 500 notched two straight days of gains and ahead of the release of minutes from the most recent meeting of the Federal Reserve. Investors will ...
Research and Markets: Global Fabry Disease Pipe... [Published Business Wire Health News - Jun 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xs3qs6/fabry_disease) has announced the addition of the "Fabry Disease Pipeline Highlights - 2014 Update" report to their offering. The latest report Fabry Disease ...
Research and Markets: Fabry Disease - Pipeline ... [Published Business Wire Health News - Jun 10 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fhx488/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information ...
Orphan designation: 1-Deoxygalactonojirimycin h... [Published Orphan designations - May 08 2014]
[tt] [GRG] Pompe's Disease [Published TranshumanTech - Jan 27 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Pompe's Disease... -- Steve Coles "Agonizing Choices for Lives Saved by Miracle Drugs" by Geeta AnandSeven months ago, Megan Crowley made a gutsy decision: to undergo ...
1

Press Releases

sort by: Date | Relevance
Amicus Therapeutics Analyst Report; Solid Pipel... [Published Financial Services - Jul 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.